Moderna MRNA Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 210.2%+32.5pp | 177.7%-14.4pp | 192.1%-126pp | 318.1%-32.6pp | |
| Operating margin | -537%-170pp | -366.8%-312pp | -54.3%-305pp | 250.8%+36.9pp | |
| Net margin | -484.8%-86.2pp | -398.6%-332pp | -66.9%-291pp | 224.3%+26.9pp | |
| Returns | |||||
| Return on equity | -115%+14.5pp | -129.5%-111pp | -18.4%-406pp | 387.8%+37.9pp | |
| Return on invested capital | -138.4%-6.6pp | -131.8%-118pp | -13.4%— | —— | |
| Efficiency | |||||
| Asset turnover | 0.7×-0.3× | 1×-0.7× | 1.7×-2.1× | 3.9×+0.7× | |
| Liquidity | |||||
| Current ratio | 15.4×-0.8× | 16.2×+3.4× | 12.7×+4.2× | 8.6×+2.9× | |
| Leverage | |||||
| Debt-to-equity | 0.4×0.0× | 0.4×0.0× | 0.4×+0.1× | 0.3×-0.1× | |
| Per Share | |||||
| Book value per share | $96.46-21.1% | $122.33-24.8% | $162.64-5.8% | $172.64+114% | |
| Valuation | |||||
| Market capitalization | $42.9B-66.5% | $128B-30.0% | $182.78B-24.3% | $241.51B-40.7% | |
| Price / sales | 17.2×-9.7× | 26.9×+8.8× | 18.1×+6.8× | 11.3×-40.5× | |
| Price / book | 4.6×-6.1× | 10.7×-0.8× | 11.5×-1.9× | 13.4×-37.3× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Moderna's profit margins?
- Moderna (MRNA) runs a 22.1% gross margin and a -153.3% operating margin, with a -143.6% net margin.
- Where do Moderna's ratios come from?
- Every ratio is computed from Moderna's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
